Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9540084 | 0.95 | HSD17B10 (0.51) | CTSVCTSLHSD17B10KDM4EALDH1A1 | |
| SCHEMBL28337285 | 0.89 | RAB9A (0.54) | CTSVCTSLHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6191956 | 0.82 | KDM4E (0.53) | CTSVCTSLHSD17B10KDM4EALDH1A1 | |
| SCHEMBL28847978 | 0.81 | HPGD (0.43) | HSD17B10KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL26611803 | 0.80 | KDM4E (0.50) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL11333762 | 0.79 | KDM4E (0.56) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL26136040 | 0.78 | ADORA3 (0.41) | CTSVCTSLHSD17B10KDM4EALDH1A1 | |
| SCHEMBL1586540 | 0.76 | PARP1 (0.55) | CTSVCTSLHSD17B10KDM4EALDH1A1 | |
| SCHEMBL16914813 | 0.76 | KDM4E (0.53) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL12282010 | 0.75 | APP (0.65) | HSD17B10KDM4EALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-8569317-B2 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-1844780-A2 | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | Novartis Pharma AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2006-04-13 | — | — | US | disclosed |
| EP-1585521-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-20040180912-A1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| WO-2004056365-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| EP-1401451-A2 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102782-A2 | QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
| US-6358959-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2000043374-A1 | POLYAZANAPHTHALENONE DERIVATIVES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-3723432-A | 1-SUBSTITUTED-4-ARYL-2(1H)-QUINAZOLINONES AND THEIR PREPARATION | SANDOZ AG | 1973-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | CTSV 380/4885CTSL 301/4885HSD17B10 1329/4885 |
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | CTSV 1335/4885CTSL 1010/4885HSD17B10 417/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | CTSV 1335/4885CTSL 1010/4885HSD17B10 417/4885 |
| US-20040180912-A1 | Quinazoline derivatives | PTH1R, PTMS, CALCA | CTSV 591/4885CTSL 90/4885HSD17B10 3883/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | CTSV 1335/4885CTSL 1010/4885HSD17B10 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.